Dr. Sasha C. Davis, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Texas A & M University System, Hsc, College of Medicine (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 825
Licensed in Texas since 2016, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: Texas A & M University System, Hsc, College of Medicine
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
TX license Q9523 (first issued 2016; active) -
Internal Medicine Physician
TX license Q9523 (first issued 2016; active) - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Christus Mother Frances Hospital Tyler, TX
- Christus Mother Frances Hospital- Jacksonville Jacksonville, TX
Medical groups
- Texas Oncology PA (1,014 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 825
- Services billed
- 142,448
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 17,850 | 31 |
| Injection, oxaliplatin, 0.5 mg | 9,740 | 19 |
| Injection, pembrolizumab, 1 mg | 9,000 | 22 |
| Injection, nivolumab, 1 mg | 8,140 | 13 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 7,070 | 23 |
| Injection, paclitaxel, 1 mg | 6,702 | 24 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 5,940 | 14 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 5,790 | 57 |
| Injection, iron sucrose, 1 mg | 4,500 | 19 |
| Injection, dexamethasone sodium phosphate, 1 mg | 2,031 | 122 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Tyler, TX | 144 |
| Letrozole Other prescribers in Tyler, TX | 104 |
| Tamoxifen Citrate Other prescribers in Tyler, TX | 80 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Tyler, TX | 71 |
| Gabapentin Other prescribers in Tyler, TX | 55 |
| Dexamethasone Other prescribers in Tyler, TX | 55 |
| Acyclovir Other prescribers in Tyler, TX | 48 |
| Alendronate Sodium Other prescribers in Tyler, TX | 43 |
| Exemestane | 37 |
| Prednisone Other prescribers in Tyler, TX | 36 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 15 companies reported 34 payments worth $748 in total to this clinician.
| AbbVie Inc. | $163 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $98.30 |
| Tempus Ai, Inc | $92.58 |
| Novartis Pharmaceuticals Corporation | $59.99 |
| E.r. Squibb & Sons, L.l.c. | $59.03 |
| Janssen Biotech, Inc. | $46.79 |
| Pfizer Inc. | $38.90 |
| Merck Sharp & Dohme LLC | $27.93 |
| Food and Beverage | $748 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 4 companies. The companies reported $91,150 in research payments for these studies, mostly to the institutions running them.
- A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06246916 - A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual…
AstraZeneca Pharmaceuticals LP - Phase III in CDK4 6 inhibitor experienced PIK3CA mutant HR HER2 metastatic breast cancer
Genentech, Inc. - A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER)
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.